|
IPHAF
|
if I´m not mistaken inflazyme´s trials were rather unsucessful...
|
|
IPHAF
|
where do I find insider transactions?
Link would be nice.
Is yatscoff still...
|
|
IPHAF
|
Time Price Shares $ Change Buyer Seller
09:37 0.860 500 +0.100 ...
|
|
IPHAF
|
In 2001 a novartis scientist was the leading author of this publication...
|
|
IPHAF
|
http://blog.canoe.ca/hicksonsix/2007/09/27/yatscoff_decides_to_retire_from...
|
|
IPHAF
|
asp0485 is no threat to 247
it is to be used with prograf.
it´s not a...
|
|
IPHAF
|
Either Roche opts in on the stipulated terms or they are out.
the downside...
|
|
IPHAF
|
http://www.rochetransplant.com/research/product_pipeline.aspx
|
|
IPHAF
|
you don´t want to risk the integrity of clinical trials, wicch cost tens...
|
|
IPHAF
|
Yatscoff,Foster Freitag and 2 Roche scientists collaborated on this work...
|
|
IPHAF
|
Lux plans to file for approval in late 2008 for uveitis.
What´s more:&...
|
|
IPHAF
|
cyclo had sales of at least 1.3 billion USD in 2006 according to tis NYT...
|
|
IPHAF
|
I hope we´ll see 50 cents soon.
then it´s time to average down...
|
|
IPHAF
|
Is it possible that payments from our partners(roche,lux or atrium) could...
|
|
IPHAF
|
what does it mean?
or doesn´t it mean anything?
|
|
IPHAF
|
I meant it went without saying that bad news for roche and cellcept is not...
|
|
IPHAF
|
...for CellCept
http://news.yahoo.com/s/ap/20071029/ap_on_he_me/transplant...
|
|
IPHAF
|
As long as the science looks solid I´m not overly concerned.
Yeah...
|
|
IPHAF
|
near a buck?
so bucking what!
what the buck do I care.
|
|
IPHAF
|
internal cross , I guess, at PI Financial at 11:42 @ 1.10, volume 541.700.
|